How NRF2 affects inflammation and tumor growth in breast cancer
Official title: NRF2 suppression of inflammatory signaling and its role in tumor progression
Funded at Fred Hutchinson Cancer Center · NIH-10943799 · Data updated 2026-11-12
This study is looking at how a protein called NRF2 affects the growth and spread of breast cancer, with the hope of finding new ways to help prevent or treat it, so that patients can have better options for managing their condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $597,119 |
| NIH project number | 1R01CA292658-01 |
| Project ID | NIH-10943799 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with breast cancer, particularly those at risk of metastasis or recurrence.
✕Less likely to help
Patients with non-epithelial cancers or those who are not currently diagnosed with breast cancer may not benefit from this research.
What this research studies
This research investigates the role of NRF2, a transcription factor, in the spread and recurrence of breast cancer. By examining how NRF2 influences cancer cell survival and metastasis, the study aims to uncover new therapeutic pathways that could prevent or treat metastatic breast cancer. The approach includes analyzing tumor samples and utilizing advanced techniques like CRISPR to understand the molecular mechanisms at play. Patients may benefit from insights that could lead to more effective treatments targeting tumor recurrence and spread.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the risk of breast cancer recurrence and metastasis.
How similar studies have gone: Other research has shown promising results in targeting NRF2 pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Alvarez, James V — Fred Hutchinson Cancer Center
- Study coordinator: Alvarez, James V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.